Vivo Capital’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,684,109
| Closed | -$57.8M | – | 48 |
|
|
2025
Q4 | $57.8M | Hold |
2,684,109
| – | – | 3.74% | 6 |
|
|
2025
Q3 | $41M | Hold |
2,684,109
| – | – | 3.3% | 6 |
|
|
2025
Q2 | $23.8M | Hold |
2,684,109
| – | – | 2.43% | 9 |
|
|
2025
Q1 | $21M | Hold |
2,684,109
| – | – | 2.78% | 5 |
|
|
2024
Q4 | $28.2M | Hold |
2,684,109
| – | – | 3.16% | 5 |
|
|
2024
Q3 | $35.2M | Sell |
2,684,109
-1,287,990
| -32% | -$19.6M | 2.91% | 10 |
|
|
2024
Q2 | $55.8M | Hold |
3,972,099
| – | – | 5.16% | 6 |
|
|
2024
Q1 | $67.1M | Sell |
3,972,099
-124,329
| -3% | -$1.85M | 5.27% | 5 |
|
|
2023
Q4 | $57.8M | Hold |
4,096,428
| – | – | 4.74% | 6 |
|
|
2023
Q3 | $42.2M | Buy |
4,096,428
+266,851
| +7% | +$3.57M | 4.62% | 5 |
|
|
2023
Q2 | $63.1M | Buy |
3,829,577
+68,139
| +2% | +$886K | 4.36% | 4 |
|
|
2023
Q1 | $34.5M | Buy |
3,761,438
+1,007,343
| +37% | +$8.28M | 2.39% | 8 |
|
|
2022
Q4 | $19.7M | Sell |
2,754,095
-182,998
| -6% | -$1.28M | 2.27% | 16 |
|
|
2022
Q3 | $14.7M | Hold |
2,937,093
| – | – | 1.62% | 18 |
|
|
2022
Q2 | $7.17M | Hold |
2,937,093
| – | – | 0.72% | 30 |
|
|
2022
Q1 | $20.1M | Hold |
2,937,093
| – | – | 1.38% | 16 |
|
|
2021
Q4 | $23.7M | Hold |
2,937,093
| – | – | 1.43% | 17 |
|
|
2021
Q3 | $28.8M | Hold |
2,937,093
| – | – | 1.29% | 18 |
|
|
2021
Q2 | $19.8M | Hold |
2,937,093
| – | – | 0.86% | 26 |
|
|
2021
Q1 | $26.6M | Sell |
2,937,093
-589,000
| -17% | -$4.76M | 0.93% | 23 |
|
|
2020
Q4 | $23.6M | Hold |
3,526,093
| – | – | 1.05% | 21 |
|
|
2020
Q3 | $17.8M | Hold |
3,526,093
| – | – | 1.03% | 26 |
|
|
2020
Q2 | $28.5M | Sell |
3,526,093
-49,331
| -1% | -$435K | 2.04% | 12 |
|
|
2020
Q1 | $28.4M | Buy |
+3,575,424
| New | +$27.5M | 2.57% | 10 |
|
Other funds holding AVDL
Vivo Capital's AVDL Position: Q1 2026 in Review
Vivo Capital sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 2,684,109 shares — an estimated $57.8M sold.
Vivo Capital first reported a position in AVDL in Q1 2020 and held it in 24 quarters. The position peaked at $67.1M in Q1 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Vivo Capital reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Vivo Capital sold 2,684,109 Avadel Pharmaceuticals shares in Q1 2026, an estimated $57.8M.
- Vivo Capital first reported a position in Avadel Pharmaceuticals in Q1 2020 and held it in 24 quarters.
- Vivo Capital's Avadel Pharmaceuticals position peaked at $67.1M in Q1 2024.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.